Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ingevity corp. - NGVT

NGVT

Close Chg Chg %
59.52 0.44 0.73%

Closed Market

59.95

+0.44 (0.73%)

Volume: 128.03K

Last Updated:

Dec 24, 2025, 12:59 PM EDT

Trade Now

Company Overview: ingevity corp. - NGVT

NGVT Key Data

Open

$59.58

 Day Range

59.26 - 60.23

52 Week Range

28.50 - 61.77

 Market Cap

$2.14B

Shares Outstanding

35.96M

 Public Float

35.42M

Beta

1.40

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.82

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

350.85K

  

NGVT Performance

1 Week
 
 1.54%
 
1 Month
 
 13.94%
 
3 Months
 
 7.98%
 
1 Year
 
 46.58%
 
5 Years
 
 -19.90%
 

NGVT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About ingevity corp. - NGVT

Ingevity Corp. engages in the manufacture of specialty chemicals and carbon materials. It operates through the following segments: Performance Chemicals, Performance Materials and Advanced Polymer Technologies. The Performance Materials segment consists of automotive technologies and process purifications product families. Automotive technologies produce automotive carbon products used in gasoline vapor emission control systems in cars, trucks, motorcycles and boats. Process purifications produce a number of activated carbon products for food, water, beverage and chemical purification applications. The Performance Chemicals segment primarily addresses applications in three product families: pavement technologies, oilfield technologies, and industrial specialties. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based polymers for use in coatings, resins, elastomers, adhesives, bioplastics, and medical devices. The company was founded on March 27, 2015 and is headquartered in North Charleston, SC.

NGVT At a Glance

Ingevity Corp.
4920 O'Hear Avenue
North Charleston, South Carolina 29405
Phone 1-843-740-2300 Revenue 1.41B
Industry Chemicals: Major Diversified Net Income -430,300,000.00
Sector Process Industries Employees 1,600
Fiscal Year-end 12 / 2025
View SEC Filings

NGVT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.053
Price to Book Ratio 7.589
Price to Cash Flow Ratio 11.51
Enterprise Value to EBITDA 7.735
Enterprise Value to Sales 2.038
Total Debt to Enterprise Value 0.507

NGVT Efficiency

Revenue/Employee 878,937.50
Income Per Employee -268,937.50
Receivables Turnover 8.176
Total Asset Turnover 0.605

NGVT Liquidity

Current Ratio 1.867
Quick Ratio 1.00
Cash Ratio 0.259

NGVT Profitability

Gross Margin 30.662
Operating Margin 18.652
Pretax Margin -38.086
Net Margin -30.598
Return on Assets -18.524
Return on Equity -104.113
Return on Total Capital -26.08
Return on Invested Capital -23.679

NGVT Capital Structure

Total Debt to Total Equity 745.236
Total Debt to Total Capital 88.169
Total Debt to Total Assets 71.922
Long-Term Debt to Equity 705.174
Long-Term Debt to Total Capital 83.429
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ingevity Corp. - NGVT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.39B 1.67B 1.69B 1.41B
Sales Growth
+14.46% +19.72% +1.59% -16.92%
Cost of Goods Sold (COGS) incl D&A
911.20M 1.13B 1.27B 975.10M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
127.20M 124.90M 141.40M 108.30M
Depreciation
94.00M 91.30M 62.10M 76.10M
Amortization of Intangibles
33.20M 33.60M 79.30M 32.20M
COGS Growth
+16.19% +23.50% +12.44% -22.94%
Gross Income
480.60M 541.00M 427.50M 431.20M
Gross Income Growth
+11.30% +12.57% -20.98% +0.87%
Gross Profit Margin
+34.53% +32.47% +25.25% +30.66%
2021 2022 2023 2024 5-year trend
SG&A Expense
172.40M 195.50M 173.60M 162.60M
Research & Development
26.30M 30.30M 31.80M 28.10M
Other SG&A
146.10M 165.20M 141.80M 134.50M
SGA Growth
+23.58% +13.40% -11.20% -6.34%
Other Operating Expense
- - - 6.30M
-
Unusual Expense
101.30M 17.70M 173.80M 640.40M
EBIT after Unusual Expense
206.90M 327.80M 80.10M (378.10M)
Non Operating Income/Expense
7.60M 3.60M 3.10M (59.70M)
Non-Operating Interest Income
3.50M 6.40M 6.30M 7.70M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
51.70M 61.80M 93.30M 97.80M
Interest Expense Growth
+9.77% +19.54% +50.97% +4.82%
Gross Interest Expense
51.70M 61.80M 93.30M 97.80M
Interest Capitalized
- - - -
-
Pretax Income
162.80M 269.60M (10.10M) (535.60M)
Pretax Income Growth
-30.75% +65.60% -103.75% -5,202.97%
Pretax Margin
+11.70% +16.18% -0.60% -38.09%
Income Tax
44.70M 58.00M (4.70M) (105.30M)
Income Tax - Current - Domestic
33.80M 48.00M 28.70M 1.80M
Income Tax - Current - Foreign
15.50M 15.00M 11.30M 14.30M
Income Tax - Deferred - Domestic
(16.90M) (6.30M) (44.30M) (117.80M)
Income Tax - Deferred - Foreign
12.30M 1.30M (400.00K) (3.60M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
118.10M 211.60M (5.40M) (430.30M)
Minority Interest Expense
- - - -
-
Net Income
118.10M 211.60M (5.40M) (430.30M)
Net Income Growth
-34.90% +79.17% -102.55% -7,868.52%
Net Margin Growth
+8.49% +12.70% -0.32% -30.60%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
118.10M 211.60M (5.40M) (430.30M)
Preferred Dividends
- - - -
-
Net Income Available to Common
118.10M 211.60M (5.40M) (430.30M)
EPS (Basic)
2.9661 5.5423 -0.148 -11.8465
EPS (Basic) Growth
-32.42% +86.85% -102.67% -7,904.39%
Basic Shares Outstanding
39.82M 38.18M 36.50M 36.32M
EPS (Diluted)
2.9482 5.5002 -0.148 -11.8465
EPS (Diluted) Growth
-32.48% +86.56% -102.69% -7,904.39%
Diluted Shares Outstanding
40.06M 38.47M 36.50M 36.32M
EBITDA
435.40M 470.40M 395.30M 370.60M
EBITDA Growth
+6.07% +8.04% -15.97% -6.25%
EBITDA Margin
+31.28% +28.23% +23.35% +26.35%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 68.25
Number of Ratings 4 Current Quarters Estimate 0.688
FY Report Date 12 / 2025 Current Year's Estimate 4.49
Last Quarter’s Earnings 1.52 Median PE on CY Estimate N/A
Year Ago Earnings 3.51 Next Fiscal Year Estimate 4.867
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 3
Mean Estimate 0.69 0.90 4.49 4.87
High Estimates 0.80 0.94 4.62 5.20
Low Estimate 0.50 0.87 4.40 4.50
Coefficient of Variance 18.98 3.18 2.14 7.22

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Ingevity Corp. - NGVT

Date Name Shares Transaction Value
Apr 18, 2025 David H. Li President & CEO 123,229 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Richard A. White SVP and Pres, Perf Chemicals 15,280 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Richard A. White SVP and Pres, Perf Chemicals 15,000 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $48.26 per share 723,900.00
Feb 24, 2025 Mary Dean Hall EVP, Chief Financial Officer 33,746 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Mary Dean Hall EVP, Chief Financial Officer 32,894 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $48.26 per share 1,587,464.44
Feb 24, 2025 Phillip J. Platt SVP, Finance & CAO 28,070 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Phillip J. Platt SVP, Finance & CAO 27,889 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $48.26 per share 1,345,923.14
Feb 24, 2025 Stuart Edward Woodcock EVP, President Perf Materials 33,947 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Stuart Edward Woodcock EVP, President Perf Materials 33,437 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $48.26 per share 1,613,669.62
Feb 24, 2025 Ryan C. Fisher SVP, Gen. Counsel & Secretary 11,433 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Ryan C. Fisher SVP, Gen. Counsel & Secretary 11,275 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $48.26 per share 544,131.50
Feb 24, 2025 Steven Paul Hulme SVP and Pres, APT 3,991 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 24, 2025 Steven Paul Hulme SVP and Pres, APT 3,833 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $48.26 per share 184,980.58

Ingevity Corp. in the News